The U.S. Food and Drug Administration approved Novo Nordisk’s oral semaglutide formulation for weight loss, marking the first oral GLP‑1 authorized for obesity. Regulators cleared the pill with the same brand name, Wegovy, and included an indication to reduce major cardiovascular events similar to the injectable product. Phase‑3 data submitted to the FDA showed the highest pill dose produced roughly 16.6% mean weight loss at 64 weeks versus placebo, bringing efficacy close to the weekly injectable. Novo Nordisk said the tablet will launch in early January and expects it to broaden patient access given pill familiarity and simpler logistics compared with injections. The approval accelerates competition in the obesity therapeutics market and shifts commercial dynamics: oral dosing can lower distribution costs and expand prescribing to patients intolerant of or unwilling to inject. Clinicians and payers will watch real‑world uptake, adherence on an empty stomach requirement, and how insurers position coverage against existing injectable GLP‑1s.